---
title: "601607.SH (601607.SH) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/601607.SH/news.md"
symbol: "601607.SH"
name: "601607.SH"
parent: "https://longbridge.com/en/quote/601607.SH.md"
datetime: "2026-05-21T14:22:48.284Z"
locales:
  - [en](https://longbridge.com/en/quote/601607.SH/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/601607.SH/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/601607.SH/news.md)
---

# 601607.SH (601607.SH) — Related News

### [ShunYao's new stroke drug will launch seamless Phase II/III trials in China in the second half of the year, continuing to seek licensing and collaboration opportunities](https://longbridge.com/en/news/286543210.md)
*2026-05-15T09:55:30.000Z*
> Shunyi Pharmaceutical (6535-TW) announced that its new stroke treatment drug LT3001 (Odatroltide) has completed the seam

### [Shanghai Pharma's controlling shareholder, Shanghai Pharmaceuticals Holding Group, has cumulatively increased its holdings by 36.26 million H shares, raising its stake to 39%](https://longbridge.com/en/news/285643008.md)
*2026-05-08T00:50:00.000Z*
> Shanghai Pharma's controlling shareholder, Shanghai Pharmaceuticals Holding Group, has increased its holdings by approxi

### [CNY 329.1 billion, breaking down the sales expenses of A-share pharmaceutical and biotechnology companies last year: total amount decreased again, leading innovators increased investment, and some companies' sales expenses were on par with revenue](https://longbridge.com/en/news/285562086.md)
*2026-05-07T13:18:20.000Z*
> In 2025, the total sales expenses of the A-share pharmaceutical and biotechnology industry are approximately 329.1 billi

### [Shanghai Pharma: Rivaroxaban tablets have obtained drug registration certificates in Thailand](https://longbridge.com/en/news/285513713.md)
*2026-05-07T08:44:05.000Z*
> Shanghai Pharma announced that its subsidiary Changzhou Pharmaceutical Factory Co., Ltd. has obtained the drug registrat

### [Morgan Stanley: Shanghai Pharma's first-quarter performance meets expectations, maintains "In line with the market" rating for Shanghai Pharma A shares](https://longbridge.com/en/news/285298136.md)
*2026-05-06T02:24:03.000Z*
> Morgan Stanley released a research report stating that Shanghai Pharma's revenue in the first quarter was RMB 75.3 billi

### [Goldman Sachs: Raises Shanghai Pharma's target price to HKD 10.63, maintains "Sell" rating](https://longbridge.com/en/news/285161960.md)
*2026-05-05T06:25:04.000Z*
> Goldman Sachs released a research report stating that it has raised its net profit forecasts for Shanghai Pharma for 202

### [Shanghai Pharma: In the first quarter, achieved a net profit attributable to shareholders of RMB 1.418 billion, with steady breakthroughs in pharmaceutical research and development](https://longbridge.com/en/news/284792782.md)
*2026-04-30T14:28:06.000Z*
> Shanghai Pharma disclosed its first quarter report for 2026. During the reporting period, the company achieved operating

### [In the first quarter, Shanghai Pharma's profit increased by 6.35% year-on-year](https://longbridge.com/en/news/284530492.md)
*2026-04-29T09:10:38.000Z*
> Shanghai Pharma announced that the net profit attributable to shareholders of the listed company in the first quarter of